Economic burden of pneumococcal disease in children in Liguria, Italy

References

• Centers for Disease Control and Prevention. Pneumococcal disease - Types of infection. [accessed 2021 Sep 22]. https://www.cdc.gov/pneumococcal/about/infection-types.html.
   Google Scholar
• International Vaccine Access Center (IVAC). Johns Hopkins Bloomberg School of Public Health. VIEW-hub report: global vaccine introduction and implementation. [accessed 2021 Sep 22]. https://view-hub.org/sites/default/files/2020-08/VIEW-hub_Report_Jun2020_1.pdf.
   Google Scholar
• Georgalis L, Mozalevskis A, Martinez de Aragon MV, Garrido-Estepa M. Changes in the pneumococcal disease-related hospitalisations in Spain after the replacement of 7-valent by 13-valent conjugate vaccine. Eur J Clin Microbiol Infect Dis. 2017;36(3):1–8. doi:10.1007/s10096-016-2834-2.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control. Invasive pneumococcal disease - annual epidemiological report for 2017. [accessed 2019 Oct 4]. https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2017-invasive-pneumococcal-disease.pdf.
   Google Scholar
• Wahl B, O’Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Luksic I, Nair H, McAllister DA, Campbell H, et al. Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15. Lancet Glob Health. 2018;6(7):e744–e757. doi:10.1016/S2214-109X(18)30247-X.
   PubMed Web of Science ®Google Scholar
• Gisselsson-Solen M. Trends in otitis media incidence after conjugate pneumococcal vaccination: a national observational study. Pediatr Infect Dis J. 2017;36(11):1027–1031. doi:10.1097/INF.0000000000001654.
   PubMed Web of Science ®Google Scholar
• Ricketson LJ, Conradi NG, Vanderkooi OG, Kellner JD. Changes in the nature and severity of invasive pneumococcal disease in children before and after the seven-valent and thirteen-valent pneumococcal conjugate vaccine programs in Calgary, Canada. Pediatr Infect Dis J. 2018;37(1):22–27. doi:10.1097/INF.0000000000001709.
   PubMed Web of Science ®Google Scholar
• Syrogiannopoulos GA, Michoula AN, Tsimitselis G, Vassiou K, Chryssanthopoulou DC, Grivea IN. Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine. Infect Dis (Lond). 2016;48(10):749–753. doi:10.1080/23744235.2016.1192720.
   PubMed Web of Science ®Google Scholar
• Oligbu G, Collins S, Andrews N, Sheppard CL, Fry NK, Slack MPE, Borrow R, Ladhani SN. Characteristics and serotype distribution of childhood cases of invasive pneumococcal disease following pneumococcal conjugate vaccination in England and Wales, 2006–2014. Clin Infect Dis. 2017;65(7):1191–1198. doi:10.1093/cid/cix418.
   PubMed Web of Science ®Google Scholar
• Moreira M, Castro O, Palmieri M, Efklidou S, Castagna S, Hoet B. A reflection on invasive pneumococcal disease and pneumococcal conjugate vaccination coverage in children in Southern Europe (2009–2016). Hum Vaccin Immunother. 2017;13(6):1–12. doi:10.1080/21645515.2016.1263409.
   PubMed Web of Science ®Google Scholar
• Huang SS, Johnson KM, Ray GT, Wroe P, Lieu TA, Moore MR, Zell ER, Linder JA, Grijalva CG, Metlay JP, et al. Healthcare utilization and cost of pneumococcal disease in the United States. Vaccine. 2011;29(18):3398–3412. doi:10.1016/j.vaccine.2011.02.088.
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Ozsurekci Y, Aykac K, Hacibedel B, Ozbilgili E. Economic burden of pneumococcal infections in children under 5 years of age. Hum Vaccin Immunother. 2018;14(1):106–110. doi:10.1080/21645515.2017.1371378.
   PubMed Web of Science ®Google Scholar
• Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2013;20(Suppl 5):45–51. doi:10.1111/1469-0691.12461.
   Google Scholar
• Monali R, De Vita E, Mariottini F, Privitera G, Lopalco PL, Tavoschi L. Impact of vaccination on invasive pneumococcal disease in Italy 2007-2017: surveillance challenges and epidemiological changes. Epidemiol Infect. 2020;148:e187. doi:10.1017/S0950268820001077.
   PubMed Web of Science ®Google Scholar
• Baldo V, Cocchio S, Gallo T, Furlan P, Clagnan E, Del Zotto S, Saia M, Bertoncello C, Buja A, Baldovin T. Impact of pneumococcal conjugate vaccination: a retrospective study of hospitalization for pneumonia in North-East Italy. J Prev Med Hyg. 2016;57:E61–68.
   PubMedGoogle Scholar
• Barbieri E, Porcu G, Cantarutti A, Hu T, Petigara T, Prandi G, Scamarcia A, Giaquinto C, Cantarutti L. A retrospective database analysis to estimate the burden of invasive pneumococcal disease and unspecified invasive disease in children <15 years in the Veneto region (Italy). International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); 2020; Virtual.
   Google Scholar
• Barbieri E, Porcu G, Cantarutti A, Hu T, Petigara T, Prandi G, Scamarcia A, Giaquinto C, Cantarutti L. A retrospective database analysis to estimate the burden of pneumonia in children <15 years in the Veneto Region (Italy). Poster presented at the 12th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD); 2020; Virtual.
   Google Scholar
• Barbieri E, Porcu G, Cantarutti A, Hu T, Petigara T, Alimenti C, Prandi G, Scamarcia A, Giaquinto C, Cantarutti L. A retrospective database analysis to estimate the burden of acute otitis media in children <15 years in the Veneto region, Italy. European Society for Paediatric Infectious Diseases (ESPID) Annual Meeting; 2020; Virtual.
   Google Scholar
• Food and Drug Administration. VAXNEUVANCE™ (Pneumococcal 15-valent conjugate vaccine) prescribing information. [accessed 2021 July 21]. https://www.fda.gov/media/150819/download.
   Google Scholar
• Food and Drug Administration. PREVNAR 20 (Pneumococcal 20-valent conjugate vaccine) prescribing information. [accessed 2021 July 26]. https://www.fda.gov/media/149987/download.
   Google Scholar
• Senders S, Klein NP, Lamberth E, Thompson A, Drozd J, Trammel J, Peng Y, Giardina P, Jansen KU, Gruber WC, et al. Safety and immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine (PCV20) in healthy infants in the United States. Open Forum Infect Dis. 2020;7:S637. doi:10.1093/ofid/ofaa439.1421.
   Google Scholar
• Rupp R, Hurley D, Grayson S, Li J, Nolan K, McFetridge RD, Hartzel J, Abeygunawardana C, Winters M, Pujar H, et al. A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants. Hum Vaccin Immunother. 2019;15(3):549–559. doi:10.1080/21645515.2019.1568159.
   PubMed Web of Science ®Google Scholar
• Hurley D, Griffin C, Young M, Scott DA, Pride MW, Scully IL, Ginis J, Severs J, Jansen KU, Gruber WC, et al. Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age. Clin Infect Dis. 2021;73(7):e1489–e1497. doi:10.1093/cid/ciaa1045.
   PubMed Web of Science ®Google Scholar
• Durando P, Crovari P, Ansaldi F, Sticchi L, Sticchi C, Turello V, Marensi L, Giacchino R, Timitilli A, Carloni R, et al., Collaborative Group for Pneumococcal Vaccination in Liguria. Universal childhood immunisation against Streptococcus pneumoniae: the five-year experience of Liguria Region, Italy. Vaccine. 2009;27(25–26):3459–3462. doi:10.1016/j.vaccine.2009.01.052.
   PubMed Web of Science ®Google Scholar
• Ansaldi F, de Florentis D, Canepa P, Bandettini R, Diana MC, Martini M, Durando P, Icardi G. Epidemiological changes after PCV7 implementation in Italy: perspective for new vaccines. Hum Vaccin. 2011;7(sup1):211–216. doi:10.4161/hv.7.0.14602.
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Sticchi L, Durando P, Carloni R, Oreste P, Vercelli M, Crovari P, Icardi G. Decline in pneumonia and acute otitis media after the introduction of childhood pneumococcal vaccination in Liguria, Italy. J Int Med Res. 2008;36(6):1255–1260. doi:10.1177/147323000803600612.
   PubMed Web of Science ®Google Scholar
• Orsi A, Ansaldi F, Trucchi C, Rosselli R, Icardi G. Pneumococcus and the elderly in Italy: a summary of available evidence regarding carriage, clinical burden of lower respiratory tract infections and on-field effectiveness of PCV13 vaccination. Int J Mol Sci. 2016;17(7):1140. doi:10.3390/ijms17071140.
   PubMed Web of Science ®Google Scholar
• Orsi A, Ansaldi F, Durando P, Turello V, Icardi G. Gruppo di studio ligure sullo pneumococco. [Immunization campaign with 13-valent pneumococcal conjugate vaccine in adults in Liguria Region, Italy: one year post-introduction preliminary results]. Epidemiol Prev. 2014;38:66–72.
   PubMedGoogle Scholar
• Ministero della Salute. DGPRV 0024720-P-27/05/2010. Indicazioni in merito alla somministrazione del vaccino antipneumococcico Prevenar 13 in età pediatrica. [accessed 2021 Sep 22]. https://www.fimpcalabria.org/public/vaccinazioni/indicazioni%20in%20merito%20alla%20somministrazione%20del%20vaccino%20antipneumococcico%20prevenar%2013%20in%20et%C3%A0%20pediatrica%20(2).pdf.
   Google Scholar
• Ministero della Salute. Supplemento ordinario n. 8 alla GAZZETTA UFFICIALE 28.01.2013 - Serie generale - n. 23. [accessed 2021 Sep 22]. https://www.trovanorme.salute.gov.it/norme/renderPdf.spring?seriegu=SG&datagu=28/01/2013&redaz=13A00528&artp=1&art=1&subart=1&subart1=10&vers=1&prog=001.
   Google Scholar
• Lau WCY, Bielicki J, Tersigni C, Saxena S, Wong ICK, Sharland M, Hsia Y. All-Cause pneumonia in children after the introduction of pneumococcal vaccines in the United Kingdom: a population-based study. Pharmacoepidemiol Drug Saf. 2019;28(6):821–829. doi:10.1002/pds.4770.
   PubMed Web of Science ®Google Scholar
• Nair H, Watts AT, Williams LJ, Omer SB, Simpson CR, Willocks LJ, Cameron JC, Campbell H. Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children. BMC Infect Dis. 2016;16(1):390. doi:10.1186/s12879-016-1693-x.
   PubMedGoogle Scholar
• Darba J, Marsa A. Hospital incidence, in-hospital mortality and medical costs of pneumococcal disease in Spain (2008–2017): a retrospective multicentre study. Curr Med Res Opin. 2021;37(3):523–530. doi:10.1080/03007995.2021.1876007.
   PubMed Web of Science ®Google Scholar
• Weycker D, Farkouh RA, Strutton DR, Edelsberg J, Shea KM, Pelton SI. Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions. BMC Health Serv Res. 2016;16(1):182. doi:10.1186/s12913-016-1432-4.
   PubMed Web of Science ®Google Scholar
• Wilson KM, Torok MR, Localio R, McLeod L, Srivastava R, Luan X, Mohamad Z, Shah SS, Pediatric Research in Inpatient Settings N. Hospitalization for community-acquired pneumonia in children: effect of an asthma codiagnosis. Hosp Pediatr. 2015;5(8):415–422. doi:10.1542/hpeds.2015-0007.
   PubMedGoogle Scholar
• Shiri T, Khan K, Keaney K, Mukherjee G, McCarthy ND, Petrou S. Pneumococcal disease: a systematic review of health utilities, resource use, costs, and economic evaluations of interventions. Value Health. 2019;22(11):1329–1344. doi:10.1016/j.jval.2019.06.011.
   PubMed Web of Science ®Google Scholar
• Trucchi C, Paganino C, Orsi A, Amicizia D, Tisa V, Piazza MF, Gallo D, Simonetti S, Buonopane B, Icardi G, et al. Hospital and economic burden of influenza-like illness and lower respiratory tract infection in adults ≥50 years-old. BMC Health Serv Res. 2019;19(1):585. doi:10.1186/s12913-019-4412-7.
   PubMed Web of Science ®Google Scholar